Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2010

01-03-2010 | NON-THEMATIC REVIEW

The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment

Authors: Kelly K. Haagenson, Gen Sheng Wu

Published in: Cancer and Metastasis Reviews | Issue 1/2010

Login to get access

Abstract

Chemotherapy resistance is an important problem often encountered during the course of breast cancer treatment. In order to design rational and efficacious therapies, the molecular mechanisms used by cells to develop resistance must be investigated. One mechanism employed by cancer cells is to alter cell signaling. This review examines the role of mitogen-activated protein kinases (MAPKs) and their endogenous negative regulators, mitogen-activated protein kinase phosphatases (MKPs), in chemotherapy resistance in breast cancer. MAPK signaling is activated in response to both growth factors and cellular stress. MKPs dephosphorylate MAPKs and are part of the dual-specificity family of phosphatases. MAPKs have been shown to be involved in resistance to tamoxifen, and MKPs have been linked to resistance to treatment with doxorubicin, mechlorethamine, paclitaxel, proteasome inhibitors, and oxidative-stress-induced cell death in breast cancer. The role of MKPs in tamoxifen resistance and the elucidation of the mechanisms involved with resistance to standard chemotherapy agents need to be investigated further. Growing evidence suggests that modulating MKP-1 activity could be a viable option to make breast cancer chemotherapy more effective.
Literature
1.
2.
Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., et al. (2000). Molecular portraits of human breast tumours. Nature, 406(6797), 747–752.CrossRefPubMed
3.
Gutierrez, M. C., Detre, S., Johnston, S., Mohsin, S. K., Shou, J. N., Allred, D. C., et al. (2005). Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. Journal of Clinical Oncology, 23(11), 2469–2476.CrossRefPubMed
4.
Riggins, R. B., Schrecengost, R. S., Guerrero, M. S., & Bouton, A. H. (2007). Pathways to tamoxifen resistance. Cancer Letters, 256(1), 1–24.CrossRefPubMed
5.
Sporn, M. B., & Lipmann, S. M. (2003). Chemoprevention of cancer. In D. W. Kufe, R. E. Pollack, R. R. Weichselbaum, R. C. Bast, T. S. Gansler, J. F. Holland, et al. (Eds.), Cancer medicine (Vol. 6). BC Decker: Hamilton.
6.
Jordan, V. C. (2003). Estrogens and antiestrogens. In D. W. Kufe, R. E. Pollack, R. R. Weichselbaum, R. C. Bast, T. S. Gansler, J. F. Holland, et al. (Eds.), Cancer medicine (Vol. 6). Hamilton: BC Decker.
7.
Kurebayashi, J. (2005). Resistance to endocrine therapy in breast cancer. Cancer Chemotherapy and Pharmacology, 56(Suppl 1), 39–46.CrossRefPubMed
8.
Coley, H. M. (2008). Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treatment Reviews, 34(4), 378–390.CrossRefPubMed
9.
Bonneterre, J., Dieras, V., Tubiana-Hulin, M., Bougnoux, P., Bonneterre, M. E., Delozier, T., et al. (2004). Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. British Journal of Cancer, 91(8), 1466–1471.PubMed
10.
Vassilomanolakis, M., Koumakis, G., Barbounis, V., Demiri, M., Panopoulos, C., Chrissohoou, M., et al. (2005). First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer. Breast, 14(2), 136–141.CrossRefPubMed
11.
Ishikawa, T., Shimizu, S., Inaba, M., Asaga, T., Katayama, K., Fukuda, M., et al. (2004). A multicenter phase II study of docetaxel 60 mg/m2 as first-line chemotherapy in patients with advanced or recurrent breast cancer. Breast Cancer, 11(4), 374–379.CrossRefPubMed
12.
13.
Boutros, T., Chevet, E., & Metrakos, P. (2008). Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacological Reviews, 60(3), 261–310.CrossRefPubMed
14.
Wu, G. S. (2007). Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer. Cancer and Metastasis Reviews, 26(3–4), 579–585.CrossRefPubMed
15.
Keyse, S. M. (2008). Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer and Metastasis Reviews, 27(2), 253–261.CrossRefPubMed
16.
McCubrey, J. A., Steelman, L. S., Abrams, S. L., Lee, J. T., Chang, F., Bertrand, F. E., et al. (2006). Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Advances in Enzyme Regulation, 46, 249–279.CrossRefPubMed
17.
Cui, Y., Parra, I., Zhang, M., Hilsenbeck, S. G., Tsimelzon, A., Furukawa, T., et al. (2006). Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: A mechanism of tamoxifen resistance. Cancer Research, 66(11), 5950–5959.CrossRefPubMed
18.
Fan, M., Yan, P. S., Hartman-Frey, C., Chen, L., Paik, H., Oyer, S. L., et al. (2006). Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Research, 66(24), 11954–11966.CrossRefPubMed
19.
Kurokawa, H., Lenferink, A. E., Simpson, J. F., Pisacane, P. I., Sliwkowski, M. X., Forbes, J. T., et al. (2000). Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Research, 60(20), 5887–5894.PubMed
20.
Massarweh, S., Osborne, C. K., Creighton, C. J., Qin, L., Tsimelzon, A., Huang, S., et al. (2008). Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Research, 68(3), 826–833.CrossRefPubMed
21.
Wang, J., Zhou, J. Y., & Wu, G. S. (2007). ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells. Cancer Research, 67(24), 11933–11941.CrossRefPubMed
22.
Zhou, J. Y., Liu, Y., & Wu, G. S. (2006). The role of mitogen-activated protein kinase phosphatase-1 in oxidative damage-induced cell death. Cancer Research, 66(9), 4888–4894.CrossRefPubMed
23.
24.
Hirsch, D. D., & Stork, P. J. (1997). Mitogen-activated protein kinase phosphatases inactivate stress-activated protein kinase pathways in vivo. Journal of Biological Chemistry, 272(7), 4568–4575.CrossRefPubMed
25.
Dickinson, R. J., & Keyse, S. M. (2006). Diverse physiological functions for dual-specificity MAP kinase phosphatases. Journal of Cell Science, 119(Pt 22), 4607–4615.CrossRefPubMed
26.
Keyse, S. M., & Ginsburg, M. (1993). Amino acid sequence similarity between CL100, a dual-specificity MAP kinase phosphatase and cdc25. Trends in Biochemical Sciences, 18(10), 377–378.CrossRefPubMed
27.
Camps, M., Nichols, A., & Arkinstall, S. (2000). Dual specificity phosphatases: A gene family for control of MAP kinase function. FASEB Journal, 14(1), 6–16.PubMed
28.
Li, M., Zhou, J. Y., Ge, Y., Matherly, L. H., & Wu, G. S. (2003). The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. Journal of Biological Chemistry, 278(42), 41059–41068.CrossRefPubMed
29.
Liu, Y. X., Wang, J., Guo, J., Wu, J., Lieberman, H. B., & Yin, Y. (2008). DUSP1 is controlled by p53 during the cellular response to oxidative stress. Molecular Cancer Research, 6(4), 624–633.CrossRefPubMed
30.
Cleator, S., Heller, W., & Coombes, R. C. (2007). Triple-negative breast cancer: Therapeutic options. Lancet Oncology, 8(3), 235–244.CrossRefPubMed
31.
Kang, S. P., Martel, M., & Harris, L. N. (2008). Triple negative breast cancer: Current understanding of biology and treatment options. Current Opinion in Obstetrics and Gynecology, 20(1), 40–46.CrossRefPubMed
32.
Stockmans, G., Deraedt, K., Wildiers, H., Moerman, P., & Paridaens, R. (2008). Triple-negative breast cancer. Current Opinion in Oncology, 20(6), 614–620.CrossRefPubMed
33.
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., et al. (2007). The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clinical Cancer Research, 13(8), 2329–2334.CrossRefPubMed
34.
Reis-Filho, J. S., & Tutt, A. N. (2008). Triple negative tumours: A critical review. Histopathology, 52(1), 108–118.PubMedCrossRef
35.
Wang, Z., Xu, J., Zhou, J. Y., Liu, Y., & Wu, G. S. (2006). Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance. Cancer Research, 66(17), 8870–8877.CrossRefPubMed
36.
Wang, H. Y., Cheng, Z., & Malbon, C. C. (2003). Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Letters, 191(2), 229–237.CrossRefPubMed
37.
Small, G. W., Shi, Y. Y., Higgins, L. S., & Orlowski, R. Z. (2007). Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Research, 67(9), 4459–4466.CrossRefPubMed
38.
Small, G. W., Somasundaram, S., Moore, D. T., Shi, Y. Y., & Orlowski, R. Z. (2003). Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK. Journal of Pharmacology and Experimental Therapeutics, 307(3), 861–869.CrossRefPubMed
39.
Rojo, F., Gonzalez-Navarrete, I., Bragado, R., Dalmases, A., Menendez, S., Cortes-Sempere, M., et al. (2009). Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin. Clinical Cancer Research, 15(10), 3530–3539.CrossRefPubMed
40.
Orlowski, R. Z., Small, G. W., & Shi, Y. Y. (2002). Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. Journal of Biological Chemistry, 277(31), 27864–27871.CrossRefPubMed
41.
Small, G. W., Shi, Y. Y., Edmund, N. A., Somasundaram, S., Moore, D. T., & Orlowski, R. Z. (2004). Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Molecular Pharmacology, 66(6), 1478–1490.CrossRefPubMed
42.
Shi, Y. Y., Small, G. W., & Orlowski, R. Z. (2006). Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. Breast Cancer Research and Treatment, 100(1), 33–47.CrossRefPubMed
43.
Wu, W., Pew, T., Zou, M., Pang, D., & Conzen, S. D. (2005). Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. Journal of Biological Chemistry, 280(6), 4117–4124.CrossRefPubMed
Metadata
Title
The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment
Authors
Kelly K. Haagenson
Gen Sheng Wu
Publication date
01-03-2010
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2010
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-010-9208-5

Other articles of this Issue 1/2010

Cancer and Metastasis Reviews 1/2010 Go to the issue

NON-THEMATIC REVIEW

DNA methylation markers in colorectal cancer

OriginalPaper

Lung cancer: From single-gene methylation to methylome profiling

EditorialNotes

Preface

OriginalPaper

Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer

OriginalPaper

Stepwise progression of pulmonary adenocarcinoma—clinical and molecular implications

NON-THEMATIC REVIEW

p66Shc—a longevity redox protein in human prostate cancer progression and metastasis

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits